KR20150115086A - Health food and pharmaceutical composition for preventing or improving gastrointestinal motility disorder comprising extract of Rubus coreanus as effective component - Google Patents
Health food and pharmaceutical composition for preventing or improving gastrointestinal motility disorder comprising extract of Rubus coreanus as effective component Download PDFInfo
- Publication number
- KR20150115086A KR20150115086A KR1020140039422A KR20140039422A KR20150115086A KR 20150115086 A KR20150115086 A KR 20150115086A KR 1020140039422 A KR1020140039422 A KR 1020140039422A KR 20140039422 A KR20140039422 A KR 20140039422A KR 20150115086 A KR20150115086 A KR 20150115086A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- gastrointestinal motility
- present
- motility disorder
- active ingredient
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to Rubus The present invention relates to a health food and a pharmaceutical composition for preventing or ameliorating a gastrointestinal motility disorder disease, which comprises, as an active ingredient, an extract of a bacterium of the present invention. The bacterium extract of the present invention is harmless to the human body, And can be usefully used in therapeutic agents for exercise disorders and the like.
Description
The present invention relates to a health food for preventing or improving gastrointestinal motility disorder containing a bokbunja extract as an active ingredient and pharmaceutical compositions, and more particularly bokbunja (Rubus coreanus extract as an active ingredient, a pharmaceutical composition for preventing or treating a gastrointestinal motility disorder disease comprising as an active ingredient an effective food for preventing or ameliorating a gastrointestinal motility disorder disease, a therapeutic agent for constipation comprising an extract of bokbunja as an active ingredient, Feed additives.
Gastrointestinal motility disorders are functional symptoms related to gastrointestinal peristalsis, not histopathological and biochemical lesions of the gastrointestinal tract. Various symptoms such as gastroesophageal reflux disease, functional dyspepsia, irritable bowel disease, gastrointestinal palsy, vomiting, postoperative ileus and constipation And it is a disease with a high prevalence rate in Korea as well as advanced countries.
However, it has recently been shown that serotonin (5-HT) receptors are distributed in the gastrointestinal tract, especially in the endocrine endocrine cells, and play a central role in the peristaltic movement of the gastrointestinal tract, The development of new gastrointestinal motility promoters has been centered on serotonin - regulating drugs. However, most 5-HT 3 receptor antagonists improve the delayed gastric emptying symptoms in rats, but the improvement effect is not clear in other species including humans, and some 5-HT receptor antagonists have a high side effect on pregnant women and patients with cerebral cardiovascular disease It stopped selling. On the other hand, there is known a treatment method of relieving the symptom of gastrointestinal motility dysfunction, especially post-operative intestinal obstruction, which removes secretion from the gastrointestinal tract by aspiration of the gastric outlet when the occurrence of gastrointestinal bleeding is occurred, and sisapride has been frequently used as a drug. However, It is true. Recently, regarding the restoration of gastrointestinal function after surgery, synthetic drugs such as alvimopan, Entereg
On the other hand, Rubus coreanus Miquel) is a deciduous shrub belonging to Rosaceae. It is known as the origin of China. In Korea, Jeju and southern regions are major producing areas and harvested sown red fruits in early summer. Since ancient times, it has been known as a valuable medication as a summary of tonic, gentian, and interpolation, and has been used for weakness of the body, ambulation, oil well, urination. In addition, it is known that the bokbunja has an antioxidative effect, an effect of inhibiting the growth of Helicobacter pylori, and a hypothalamic-pituitary-gonadal axis, thereby improving the symptoms caused by the secretory function of the gonadal secretion in ovariectomized female rats.
Accordingly, the present inventors have developed a composition for preventing or treating gastrointestinal motility disorders from various bacterium of various potency.
Korean Patent No. 0532703 discloses a composition for prevention and treatment of gastrointestinal motility disorders including a herbal composition, Korean Patent Publication No. 2012-0090003 discloses a composition for preventing, treating and preventing gastrointestinal motility disorders Composition, " but the health food and pharmaceutical composition for preventing or ameliorating diseases of the gastrointestinal motility disorder containing the bacterium extract of the present invention as an active ingredient have not been disclosed.
The present invention has been made in view of the above-mentioned needs, and it is an object of the present invention to measure the survival rate of the cells treated with the bokbunja extract and the ability of the male rat to study the pyloric dynamics. As a result, The present invention has been completed.
In order to solve the above problems, the present invention bokbunja (Rubus coreanus extract as an active ingredient.
In addition, the present invention relates to the use of Rubus coreanus ) as an active ingredient. The present invention also provides a pharmaceutical composition for preventing or treating gastrointestinal motility disorders.
In addition, the present invention relates to the use of Rubus coreanus extract as an active ingredient.
In addition, the present invention relates to the use of Rubus coreanus extract as an active ingredient.
In the present invention, the effect of improving the pyloric exercise ability of male rats using the bokbunja extract was confirmed. The bramble extract of the present invention is expected to be useful for the treatment of disorders of the gastrointestinal motility disorder because it is derived from a natural product and is harmless to the human body and exhibits excellent gastric shrinking exercise effect.
FIG. 1 shows the survival rate of 293T cells according to the treatment concentration of bokbunja extract.
FIG. 2 is a graph showing the shrinkage tension of the sample treated with the bokbunja extract at different concentrations.
FIG. 3 is a graph showing the relative shrinkage tension of the sample treated with the bokbunja extract at different concentrations.
According to an aspect of the invention, the invention is bokbunja (Rubus coreanus extract as an active ingredient.
In a health food for preventing or ameliorating gastrointestinal motility disorders according to an embodiment of the present invention, the brambler extract may be a bramble hot-water extract, but is not limited thereto.
In the health food for preventing or ameliorating gastrointestinal motility disorder disease according to an embodiment of the present invention, the hot water extract of the brambler may be obtained by mixing water with brambles and culturing the brambles at 60 to 80 ° C, preferably at 70 ° C But it is not limited thereto.
In a health food according to an embodiment of the present invention, the gastrointestinal motility disorder disease may include functional dyspepsia, ulcerative dyspepsia, non-ulcer dyspepsia, gastroesophageal reflux disease, reflux esophagitis, , Constipation, irritable bowel syndrome, irritable bowelitis, diabetic gastrointestinal motility disorder, gastrointestinal motility disorder due to combination therapy, intestinal atresia due to gastrointestinal motility disorder, gastrointestinal motility disorder due to myotonic dystrophy, and non-cardiogenic chest pain But is not limited thereto.
In addition, the bokbunja extract of the present invention may be added to foods or beverages for the purpose of preventing or improving gastrointestinal motility disorders. The amount of the extract in the food or drink may be 0.01 to 15% by weight of the total food, and the health beverage composition may be added in a proportion of 0.02 to 5 g, preferably 0.3 to 1 g, based on 100 ml.
The health functional beverage composition of the present invention has no particular limitation on the other ingredients other than the above-mentioned extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tautatin, stevia extract, for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above . The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
In addition to the above, the extract of the present invention can also be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and aging agents (cheese, chocolate, etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the extract of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks. These ingredients may be used independently or in combination, and the proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.
In a health food for preventing or ameliorating a gastrointestinal motility disorder disease according to an embodiment of the present invention, the food may be a milk product, fermented milk, But are not limited to, those selected from the group consisting of sweeteners, soups, beverages, alcoholic beverages, and vitamin complexes.
In addition, the present invention relates to the use of Rubus coreanus ) as an active ingredient. The present invention also provides a pharmaceutical composition for preventing or treating gastrointestinal motility disorders.
In the pharmaceutical composition for the prevention or treatment of gastrointestinal motility disorders according to an embodiment of the present invention, the gastrointestinal motility disorder disease may include functional dyspepsia, ulcerative dyspepsia, non ulcer dyspepsia, gastroesophageal reflux disease, reflux esophagitis, Diabetic gastrointestinal motility disorder, gastrointestinal motility disorder due to combination therapy, intestinal atresia due to gastrointestinal motility disorder, gastrointestinal motility disorder due to myotonic dystrophy, and non-irritable bowel movement disorder Cardiogenic chest pain, but is not limited thereto.
The pharmaceutical composition for preventing or treating gastrointestinal motility disorders according to the present invention may comprise 0.02 to 80% by weight, preferably 0.02 to 50% by weight of the extract, based on the total weight of the composition.
The composition comprising the extract of the present invention may further comprise an appropriate carrier, excipient and diluent conventionally used in the production of a pharmaceutical composition.
The pharmaceutical dosage forms of the extract of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in suitable aggregates.
The composition containing the extract according to the present invention may be administered orally or parenterally in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols or the like, oral preparations, And can be used as formulations. Examples of carriers, excipients and diluents that can be contained in the composition containing the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Various compounds or mixtures including silicates, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, oligosaccharides, Sucrose, lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of suppository bases include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like.
The preferred dosage of the extract of the present invention varies depending on the condition and weight of the patient, the degree of disease, the type of drug, the administration route and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at a daily dose of 0.0001 to 100 mg / kg, preferably 0.001 to 100 mg / kg. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.
The extract of the present invention can be administered to mammals such as rats, mice, livestock, and humans in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.
In addition, the present invention relates to the use of Rubus coreanus extract as an active ingredient.
In addition, the present invention relates to the use of Rubus coreanus extract as an active ingredient.
The feed additive of the present invention can improve gastric motility when administered to a livestock exhibiting gastric motility-reducing symptoms. The feed additives of the present invention can be mixed and used in a conventional manner when they are mixed with livestock water.
Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
Materials and methods
1. Bokbunja Heat number Extract preparation
Distilled water was added to the bokbunja sample and incubated at 60 ~ 80 ℃ for 3 hours. The obtained extract was filtered with a filter paper (Whatman filter paper, No. 2) to remove impurities and then freeze-dried. The hydrothermal extracts were confirmed to be soluble in sterilized water as a result of solubility and used at -80 ℃ for freezing to prevent oxidation of the samples. The extract of brambled hot water obtained from this experiment is expressed as JBMI-RW.
2. Cytotoxicity test
Cytotoxicity was evaluated by cytotoxicity of a sample to normal cells using 293T cells, a human kidney epithelial cell line. 293T cells were purchased from Korean Cell Line Bank (KCLB21573) and cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS). The cells were cultured in a constant temperature incubator at 37 ° C in which 5% CO 2 was injected. The cells were cultured in a constant temperature range of 80 to 90% after observing with a phase contrast microscope.
In order to examine the stability of the sample, 293T, a human kidney epithelial cell line, which is a normal cell line, was used to express MTS (3- (4,5-dimethylthiazol-2-yl-5- (3-carboxymethoxyphenyl) -2- The cells were treated with 1.5 × 10 4 cells / well in a 96-well plate and treated with the concentrations (1, 10, 25, 50, 100 μg / ml) The cells were cultured for 24 hours at 37 ° C and 5% CO 2. After incubation, the MTS solution was added and incubated for 4 hours, and the absorbance was measured at 490 nm using a microplate reader. Respectively.
Cell survival rate (%) = (absorbance of sample-added group / absorbance of control group) x 100
3. Camouflage Yumun-dong Evaluation of athletic performance improvement efficacy
Male rats (Dawiey, 6 weeks old, 200-250 g) were raised in a rabbits maintained at 24 ± 0.5 ° C and allowed free access to water and feed. The rat was sacrificed by cervical dislocation and the mucous membrane was removed in a large glass container containing Krebs solution. The slice was cut into 2 × 5 mm. One side of the section was fixed to a tissue fixation device in a 10 ml capacity organ bath and the other side was looped and connected to an isometric muscle contraction transducer (Grass, FT-03) to give a base tension of 0.5 g. Drug administration or battle stimulation was given after a 1 hour stabilization period and the crepes solution was replaced approximately 15 minutes apart during the stabilization period. Data was recorded and stored using a data integration device (Powerlab 4/25, Adinstruments) and Chart 7.02 software. The mixture gas (95% O 2 and 5% CO 2 ) was injected during the experiment and the temperature in the bath was kept constant at 37 ± 0.5 ° C.
The nutrient solution was
4. Statistical processing
The significance of the test results was evaluated by Duncan's one-way analysis of variance (SPSS V12, New York, NY, USA).
Example 1. Bokbunja Heat number Cytotoxicity test of extract
The extracts were subjected to cytotoxicity tests. The stability of the bacterium hydrothermal extract was confirmed by using 293T cells as a normal cell. As a result, it was confirmed that the cytotoxicity was not observed up to the concentration of 100 ㎍ / ㎖ which is the highest treatment concentration, and the stability of the sample was high (FIG. 1).
Example 2. Camouflage Yumun-dong Athletic performance improvement measurement result
To confirm the gastrointestinal motility of JMBI-RW, the gastric pylorus was separated and the contraction tension was measured (Fig. 2). The shrinkage tension was calculated as the shrinkage tension of each sample concentration based on the untreated group as 100%.
The JMBI-RW group tended to increase to 117.6 ± 14.7% at 30 ㎍ / ㎖ treatment and 147.3 ± 28.4% at 100 ㎍ / ㎖ treatment (Fig. 3). These results suggest that bokbunja extract may help to improve constipation by promoting gastric motility contraction.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140039422A KR20150115086A (en) | 2014-04-02 | 2014-04-02 | Health food and pharmaceutical composition for preventing or improving gastrointestinal motility disorder comprising extract of Rubus coreanus as effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140039422A KR20150115086A (en) | 2014-04-02 | 2014-04-02 | Health food and pharmaceutical composition for preventing or improving gastrointestinal motility disorder comprising extract of Rubus coreanus as effective component |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150115086A true KR20150115086A (en) | 2015-10-14 |
Family
ID=54357298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140039422A KR20150115086A (en) | 2014-04-02 | 2014-04-02 | Health food and pharmaceutical composition for preventing or improving gastrointestinal motility disorder comprising extract of Rubus coreanus as effective component |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20150115086A (en) |
-
2014
- 2014-04-02 KR KR1020140039422A patent/KR20150115086A/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11771726B2 (en) | Composition, containing Quisqualis indica extract, for preventing or treating prostatic hyperplasia | |
| JP2007091631A (en) | Anti-helicobacter pylori agent and food and beverage containing the same | |
| US20100151057A1 (en) | Medicinal herbal extract having anti-obesity effect | |
| EP3144005A1 (en) | Composition for preventing and treating male infertility, containing mixed herbal extract as active ingredient and use thereof | |
| KR102286429B1 (en) | A composition for improving, preventing and treating bone-related disease comprising polysaccharide fraction isolated from Nelumbo nucifera leaf | |
| KR101964054B1 (en) | Pharmaceutical composition comprising extract of Lonicera japonica for prevention and treatment of Crohn's disease | |
| KR101749967B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity | |
| KR101416191B1 (en) | Pharmaceutical composition for preventing or treating cancer comprising extract of Jeju traditional citrus Palsac, Dangyusa or Iyegam as effective component | |
| KR101735061B1 (en) | Composition containing Artemisia annua extract, artemisinin or dihydroartemisinin for preventing or treating obesity | |
| KR20190070844A (en) | A composition comprising the compounds isolated from an extract of Allium sativum L. for treating and preventing muscle-related disorder | |
| KR102014922B1 (en) | Composition for improving digestive functions comprising glabridin from Liquorice | |
| JP2022110113A (en) | Pharmaceutical composition, food composition and food additive for preventing, alleviating or treating muscle loss, weakness and atrophy, containing, as active ingredient, enterococcus faecalis, culture liquid thereof or dead cells thereof | |
| KR101070476B1 (en) | Composition containing extract of black onion for prevention and treatment of Gout or Hyperuricemia | |
| KR20160011846A (en) | Anti-obesity composition containing bitter melon mixture hot water extract and manufacturing method thereof | |
| KR20150115086A (en) | Health food and pharmaceutical composition for preventing or improving gastrointestinal motility disorder comprising extract of Rubus coreanus as effective component | |
| KR20160072866A (en) | Health functional food and pharmaceutical composition for preventing or improving gastrointestinal motility disorder comprising extract of Chaenomelis fructus as effective component | |
| US20200254033A1 (en) | Composition for preventing and improving gastrointestinal disorder containing lactobacillus plantarum | |
| KR20200132286A (en) | Methods for the manufacture of health food for improving gastrointestinal disorders by using bokbunja extract | |
| JP2005022994A (en) | Hypoglycemic composition | |
| KR20200052629A (en) | Composition for enhancing immunity comprising hot water extract of skimmed perilla frutescens powder | |
| KR100560411B1 (en) | Pharmaceutical Composition for Recovering Hangover Comprising Green Tea Catechins as an Active Ingredient | |
| KR101996184B1 (en) | Adjuvant of anti-cancer agent comprising and an extract of Allium sativum L. for treating and preventing cachexia | |
| KR101338532B1 (en) | Composition for preventing or treating colon cancer containing extract of sea cucumber | |
| KR102229177B1 (en) | Composition for preventing or treating sarcopenia comprising extract of rosemary and soybean | |
| KR101552816B1 (en) | Compositions for preventing or treating benign prostatic hyperplasia comprising extracts of Veratrum nigrum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |